Business, Drugs and Pharmaceuticals, Free News Articles

NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass. -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease. Dr. Mansour brings a wealth of expertise in infectious disease research where he leads an independent laboratory at the Massachusetts General Hospital (MGH). He is a leading authority guiding investigative studies on COVID-19 treatments and biomarkers which includes serving as Principal Investigator for Phase 3 COVID-19 studies.

As Medical Advisor, Dr. Mansour will direct NED's clinical trial initiative for NED-260 to establish the treatment's safety and efficacy for COVID-19 patients. NED-260 is a rationally designed, combination treatment that has the potential to address COVID-19 viral replication and entry based on its multiple mechanisms of action. Through its multifaceted approach to address major processes integral to COVID-19's progression and how it infects the cell, NED-260 may fulfill a critically important niche in the treatment and prevention of mild-to-moderate illness in the majority of people who are at risk for COVID-19 infection. NED is planning to conduct a Phase 2, randomized, placebo-controlled study of NED-260 in mild-to-moderate COVID-19 patients.*

"This study offers a chance to look at an oral treatment for COVID-19," said Dr. Mansour. "Taken directly after diagnosis, the combination is aimed at interrupting disease progression - and potentially speeding up a patient's recovery time. The trial will also explore the use of NED-260 as a potential prophylaxis, to prevent infection."

"The contribution of Dr. Mansour's expertise and considerable insight will be invaluable as we establish the safety and efficacy of NED-260 as a COVID-19 treatment," stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems. "We are eager to commence the NED-260 clinical trials with Dr. Mansour's seasoned guidance. The time is now to develop an early treatment solution and preventative of infection."

"Dr. Mansour is an outstanding addition to our team of accomplished medical advisors at NED Biosystems," stated Dr. Geoffrey Ling, Office of the CEO, Scientific Advisory Board, Board of Directors, NED Biosystems and advisor to the U.S. Government's COVID-19 Task Force. "His prominence in the field of infectious disease research and deep expertise will help propel our efforts to bring our uniquely comprehensive treatments to the broader patient community. We are delighted to welcome him to the team."

Dr. Mansour leads a team of medical research scientists at the Mansour Laboratory that focuses on developing novel cellular diagnostics and therapies for invasive fungal infections. He is also a practicing physician specialized in infectious disease at MGH. Dr. Mansour obtained an MD and PhD from Boston University and completed his residency and served as a fellow at the MGH.

About NED Biosystems(TM)

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments to provide multifaceted approaches to affect multiple key disease processes. Beginning with a focus on patients and their families, NED seeks to dramatically improve patient outcomes with combination treatments comprised of agents with well-established safety and tolerability profiles. NED's treatment approach is to afford patients high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations, but also in economically challenged regions globally.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-260 is pending approval by the FDA post clinical trials.

PHOTO link for media: https://www.Send2Press.com/300dpi/20-1006s2p-ned-michael-mansour-300dpi.jpg

Caption: Michael Mansour, MD, PhD, NED Biosystems' New Medical Advisor of Infectious Disease.

Related link: https://nedbiosystems.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches

US Pharmaceutical Corporation® Introduces Patented Hylafem® pH Vaginal Suppositories Consisting of Boric Acid in a Probiotic Blend

DECATUR, Ga. -- US Pharmaceutical Corporation(R), the probiotic and nutritional supplement company, launches Hylafem(R) pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women's vaginal health issues.

Introducing Hylafem(R) pH, a patented, over-the-counter, probiotic-based vaginal suppository with an easy applicator. Hylafem(R) pH effectively addresses symptoms of bacterial vaginosis (BV), urinary tract infections, vaginal bacterial and yeast infections and post-menopausal dryness, with minimal to no side effects.

"Developing new and innovative products is a passion of mine. My focus is on delivering effective alternatives to traditional pharmaceutical therapies. I am inspired by the ever-evolving benefits of microbes in and on our bodies that are being revealed," said Allison Krebs, CEO, US Pharmaceutical Corporation.

Hylafem(R) pH relies on the power of probiotics to restore the vaginal microbiome to a state of equilibrium. One fast-dissolving probiotic suppository capsule, adhering to the mucosal membrane, lowers pH from 7.0 to 4.5 within 5 minutes after administration. Most over-the-counter oral probiotics may not even reach the vaginal canal, but Hylafem(R) pH directly delivers the probiotics necessary to balance and maintain a healthy vaginal microbiome, which may help stimulate the immune response during vaginal infections.

Easy to self-administer, with none of the potentially dangerous side effects associated with clindamycin, and none of the messiness of metronidazole gels, Hylafem(R) pH is affordable, manufactured and produced in FDA-registered facilities, and provides effective relief, in many instances, with one dose in one day.

NDC 52747-0255-03
U.S. Patent No: 6,797,266 and 10,258,567

OUR EFFECTIVE INGREDIENTS

* Probiotics: Hylafem(R) pH releases 200 billion CFUs of Lactobacillus casei (KE-99) and 100 billion CFUs of Lactobacillus gasseri. Lactobacillus casei produces lactic acid that helps provide a healthy vaginal environment; Lactobacillus gasseri produces bacteriocin, a protein that helps fight bad bacteria.
* Homeopathics: Boricum Acidum 3XHPUS is a homeopathic dilution that combats yeast infections.
* Antioxidants: Vitamins E and C fight free radicals.
* Plant-based capsule: The capsule is made of pullulan, a plant-based material that stabilizes the organism for maximum effectiveness and extended shelf-life.

WHAT HYLAFEM(R) pH DOES

• Treats vaginal bacterial and yeast infections
Bacterial Vaginosis (BV) is one of the most common infections in women of reproductive age. BV occurs when there is an imbalance of good vs. harmful bacteria in the vaginal microbiome.

• Rebalances vaginal pH and restores vaginal health
A rise in pH can increase the likelihood of infection. One vaginal suppository repopulates the vagina with lactobacilli, the predominant bacteria in healthy women, creating an unfavorable environment for the growth of bacteria including pathogens.

• Helps relieve burning, itching, irritation, inflammation and dryness, inside and out

• Helps reduce odors due to vaginal infection

* Additional applications Also recommended for prevention and maintenance of post-menopausal, post-childbirth, post-surgical, chemotherapy, diabetes-related conditions. In the U.S., 32 million post-menopausal women seek relief from the chronic pain associated with vaginal dryness, cracking and itching.

• Reduces recurrence Clinical management of BV has made little progress in the past two decades. The first-line antibiotic therapy showed 70 to 80 percent curative rates after four weeks of treatment, however, high rates of recurrence occurred within 12 months, reaching 40 to 50 percent.

SUPERIOR BENEFITS

Many products are designed to provide relief for the symptoms associated with BV, UTI and vaginal dryness. But clinical studies show that, unlike Hylafem(R) pH, traditional treatments do not directly address the main causal imbalance of the lactobacillus-dominated (healthy) vaginal flora in the vaginal microbiome and therefore recurrence is frequent.

Hylafem(R) pH is:

* Highly effective and offers sustained relief About 21 million American women under the age of 49 suffer from an outbreak of BV at least once per year. According to the Centers for Disease Control (CDC), most have a recurrence within 6 to 12 months, and enter a cycle of antibiotic use.

* Targeted with an improved side-effect profile: Non-hormonal, reduced cancer risk, blood clot risk.

* Non-prescription: Available over-the-counter

* In powder form: Reduces messiness post-application

* Simple and effective: Contains only six ingredients, delivered in a plant-based capsule.

Hylafem(R) pH can be purchased at https://bit.ly/hylafemph for $29.95 MSRP.

About US Pharmaceutical Corporation

US Pharmaceutical Corporation(R) is a family-operated pharmaceutical company based in Atlanta, Georgia, with a specialty in patented prescription nutritional supplements and probiotics. We are proud to serve our patients and customers across the USA, under the same ownership, since 1954. Our team has a lifelong commitment to health and well-being, with probiotics being a consistent part of their daily regimen.

When we develop new medications and devices, the first question we ask ourselves is, "What would we like if we were the patient?" That's how we developed our slogan "Products designed with the patient in mind." US Pharmaceutical Corporation(R) provides product literature, free samples and product vouchers to health-care providers.

Learn more at: https://www.uspco.com/product_literature.aspx?pid=436

Media Only Contact:
Nancy Wilson
Of US Pharmaceutical Corporation
+1-770-987-4745 EXT. 176
n.wilson@uspco.com
web: https://uspco.com/

*LOGO link for media: http://www.Send2Press.com/300dpi/20-0817s2p-UDPHARM-300dpi.jpg

Disclaimer: These statements have not been evaluated by the FDA. This product is not intended to cure, diagnose, or prevent any disease.

Related link: https://www.uspco.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles, Manufacturing

Thar Process Expands into India to Focus on Pharmaceutical Purification Market

PITTSBURGH, Pa. -- Thar Process, Inc - an American manufacturer of high-tech supercritical CO2 extraction and purification equipment - is proud to announce the signing of a new exclusive distribution deal with YMC India (a subsidiary of YMC Co. Ltd., JAPAN). YMC India will now provide Thar's supercritical extraction and chromatographic systems and expertise to the greater India region.

Through this new partnership, Thar Process is furthering their overall mission to design, develop and distribute top-tier quality equipment for the food and pharmaceutical communities, with a dedication and responsibility as an industry leader to help push the emerging market forward and set a higher standard - what Thar calls "Sustainable + Trust."

YMC India proudly leads India in sales of bulk chromatography media and industrial scale chromatography equipment to the world's largest pharmaceutical manufacturing market. YMC Co. Ltd., JAPAN is internationally reputed for its strong background in stationary phases / chromatographic media for the pharmaceutical industry while also selling preparative to process-scale normal and reverse phase liquid chromatography (LC) equipment.

While YMC India will continue to sell those systems, the Thar Process series of SuperFast CO2 Extraction(tm) and Isolator SFC(tm) systems expands their reach into a new markets including the extraction Ayurvedic natural medicines, essential oils, flavors, fragrances; the purification of hemp and palm oil plus chiral separations and impurity remediation for pharmaceuticals.

The partnership between Thar Process and YMC India brings together knowledgeable and experienced engineering with the highest level of pharmaceutical industry-specific expertise to further advance the evolving technology and provide innovative products to the South Asian market.

About Thar Process

Thar is committed to bringing innovation to the industry and providing a reliable source for all natural product oil extraction needs, providing clients the training and education to become a premium FDA registered, USDA Organic processor - like Thar in its Pittsburgh HQ.

Please visit https://tharprocess.com/.

About YMC India

YMC India Pvt. Ltd is a subsidiary of YMC Co. Ltd., JAPAN. with its head office at New Delhi and sales network PAN India. YMC India hold its strong presence throughout the pharmaceutical industry with its diversified product portfolio having column chemistry, Bulk Media, Flash chromatography, large scale HPLC purification systems and large-scale DAC columns and other lab consumables coupled with a highly qualified & dedicated workforce of 50 people. YMC India owns a Custom Purification LAB at Hyderabad where all the application support to our end user is provided.

Please Visit https://ymcindia.com/.

Related link: http://tharprocess.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients

PARK CITY, Utah -- Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients' lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.

As a leading cause of death in infected patients, SARS-CoV-2 coronavirus-induced respiratory system damage in Covid-2 disease presents a significant and growing cause for concern worldwide. Based on the ability of PhenT to protect brain cells in neurological disorders, Aristea expects PhenT to shield lung cells and prevent COVID-19 patient's progressing into Silent Hypoxia, In Silent hypoxia insufficient oxygen reaches the blood as it passes through the lungs. It is a complication in COVID-19 that may require oxygen administration, intubation to allow machine-controlled breathing for patients associated with poor outcomes, and lead to death.

COVID-19

Coronavirus-induced respiratory system damage occurs even in persons who are not obviously symptomatic or asymptomatic but infected with SARS-CoV-2 coronavirus.

In healthy persons, lipids and proteins protect the alveoli - tiny air sacs in the lungs. These lipoproteins protect the alveoli from collapsing and failing to inflate during inhalation. In lungs battling COVID-19, viral induced damage removes the lipid and protein protection of alveoli Alveolar cells collapse and no longer adequately oxygenate the blood of the patient. Patients with this complication rapidly further damage lung tissue by overstretching with inspiration or ventilation. This risk requires an intervention to prevent progression in Silent Hypoxia.

PhenT

PhenT has been shown to block cell dysfunction and death in cultured cells and in five animal models of head trauma, stroke, Alzheimer's disease and nerve gas toxicity. For COVID-19, this protection could extend alveolar cellular function, maintaining their lipoprotein production in alveoli. This action raises the functioning capacity of the lung to maintain oxygen saturation of blood. With this protection of alveoli, lung structures are saved from overstretching and succumbing to the damage observed in progressive SARS-Cov-2 virus infections.

About Aristea Translational Medicine Corp.

Aristea Translational Medicine Corp. is a Utah-based small business. Since its incorporation in 2000, with others located at the National Institute on Aging, NIH, and at U.S., Canadian, and U.K. universities, Aristea has investigated the sources of failures in therapeutic drug developments and methods for overcoming unnecessary failures.

Beginning in 2010, with investigators at the National Institute on Aging, Aristea turned its expertise in drug development to clinical pharmacological research that has led to the use of PhenT and its proposed applications for preventing cell dysfunction and death in COVID-19 disease.

With the support of Aristea and a $4 million, five-year grant from the National Institute of Aging, collaborators at the University of Southern California, U.S. and at the University of Exeter, U.K. are carrying out clinical trials testing PhenT as a treatment to arrest progression in Alzheimer's disease. Aristea has PhenT patents and patents pending and emphasizes that this is an opportunity announced only to facilitate empirical evaluation.

Learn more: https://aristeatm.com/

Aristea Translational Medicine Corp., 3435 Cedar Drive, Park City UT 84098

Related link: https://aristeatm.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif. -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

During the Phase 1b trial, ROKiT Pharma's goal will be to determine the safety and tolerability of the drug in humans, as well as understand the pharmacokinetic and pharmacodynamic properties. If ROK-001 gains IND approval, ROKiT Pharma would like to open its first clinical trial during the summer of 2020. Discussions are currently underway with two prominent hospitals for this trial.

"The University of Sydney found the naturally occurring compounds on Kangaroo Island, we then completed our multiyear process of developing the synthetic processes and patenting the compound and related analogs," said Dean Becker, chairman and CEO of ROKiT Pharma and globally recognized leader in IP strategy. "Our plan is to produce large quantities of the drug - enough for universal need - so that we can really help people combat this disease through more natural sources. Unleashing nature is our goal - we want to provide these potentially life prolonging drugs, in oral pill form, at a projected cost under $1,500 per month."

The patented chemical platform of ROKiT Pharma's key drugs have unprecedented in vitro and in vivo efficacy on 29 major types of cancer (intriguingly, showing activity on p53, AP-1, and NF-kB). Importantly, selective toxicity of ROK-001 on cancer cells rather than non-neoplastic (healthy) cell lines account for its' high therapeutic index, while safety profile evaluations confirm that the compound exerts no genotoxicity nor cardiotoxicity.

Given these results, ROKiT Pharma narrowed its focus for its' first clinical trial to some of the worst cancers that have no current cure - pancreatic and brain (specifically Glioblastoma Multiforme and patients who have had metastases to the brain from other organs).

"Once ROKiT Pharma is able to get FDA approval in one adult cancer type, we plan to divert our focus to childhood cancers," said John Paul DeJoria, ROKiT co-founder and founder of Paul Mitchell Systems and Patron Tequila. "As ROKiT continues to grow globally, we are continuing to add companies that really fulfill our humanitarian goals. Success unshared is failure."

The naturally derived anticancer compounds used to create ROK-001 were discovered through the propolis of Ligurian honey bees only found on Kangaroo Island, which lies off the mainland of South Australia. Propolis is a mixture of beeswax, saps and resins.

In animal studies, ROK-001 demonstrated great efficacy in a multitude of cancer models including pancreatic, melanoma, kidney, bladder, and breast, some in as early as seven days post-oral treatment. Aside from efficacy information, ROK-001 was specifically formulated for oral delivery that not only demonstrated nice biodistribution, but it also revealed that ROK-001 can cross the blood-brain barrier in mice. This discovery led to the decision to target brain cancers.

ROKiT Pharma hopes to fast track this relatively low-toxicity drug for patients with the most deadly cancers. With any proven efficacy in the Phase 1b clinical trial, the FDA may allow an immediate Phase 2 trial to start with an expanded cohort and patient population.

Upon IND approval of ROK-001, the company plans to make the drug available for "Compassionate Use" as is now allowed under the "Right To Try Act" that President Trump signed in 2018.

ROKiT Pharma is presently designing and planning a manufacturing facility (or contract manufacturing facility) in Puerto Rico to act as an established hub for global distribution.

"As the ROKiT brand's awareness continues to grow through our global sports sponsorships - ROKiT Williams Racing Formula 1, ROKiT Venturi Racing Formula E, the Houston Rockets, the Las Vegas Raiders - we are elated to be aggressively entering the pharmaceutical marketplace," said Jonathan Kendrick, co-founder of ROKiT.

The company is optimistic that ROK-001 will move straight into at least one Phase 2 trial and is currently adding philanthropic investors to its capital base.

If there is interest in learning more about ROKiT Pharma or for philanthropic inquiries, please contact info@rokitpharma.com for further information.

About ROKiT Pharma

ROKiT Pharma is a late stage preclinical pharma company focusing its research efforts on cancer. The corporation has an extensive global intellectual property portfolio. Research was developed at and in conjunction with the University of Sydney.

Additional information (*new site under construction Q2/2020): https://www.rokitpharma.com/

Media Contact:
Kristyn Clark
Senior PR Manager
ROKiT Pharma
Tel: (805) 231-1572
kristyn.clark@rokit.com

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0402s2p-rokit-pharma-300dpi.png

Related link: https://www.rokitpharma.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Manufacturing, Product Launches

Boothwyn Pharmacy in Kennett Square Now Manufacturing Hand Sanitizer

KENNETT SQUARE, Pa. -- Boothwyn Pharmacy, a PCAB-accredited compounding pharmacy located mere minutes from the heart of Kennett Square, Pennsylvania, has dedicated resources to manufacture hand sanitizer.

In response to the rising number of COVID-19 cases, the medical supply shortages created by it, and the increase in reports of homemade hand sanitizers, the FDA has given approval to accredited compounding pharmacies to commence the production of hand sanitizers.

On March 14, 2020, the FDA released new guidance for industry policy regarding the "Temporary Compounding of Certain Alcohol-Based Hand Sanitizers During the Public Health Emergency" to address the need for safe and properly prepared hand sanitizing products that have become commercially unavailable.

Committed to the health and wellbeing of the community, Boothwyn Pharmacy produced its first batch of hand sanitizer on Monday, March 23. This product was compounded in accordance with guidelines set by the FDA and recommendations from the World Health Organization. It contains 75% Isopropyl Alcohol and was made in a state-of-the-art PCAB and NABP-accredited laboratory.

Louis Micolucci, the CEO of Boothwyn Pharmacy, donated the first batch to the Kennett Square and East Marlborough Township police departments and the Longwood Fire Company to ensure the safety of local first responders.

Their hand sanitizer is now available online at https://www.bpimedicalsupply.com/CTGY/COVID19-SUPPLIES.html and can be shipped right to your door.

It is also available at both of their locations: Boothwyn Apothecary in Boothwyn, Pennsylvania, and Boothwyn Pharmacy in Kennett Square, Pennsylvania. Curbside service is available and they will bring hand sanitizer right to your car. Please call ahead to ensure hand sanitizer will be ready for you upon arrival.

About Boothwyn Pharmacy:

Helping the community is not simply an utterance of words for the Boothwyn Pharmacy family, but rather a philosophy that has been engrained in each and every member since their doors first opened in 1933.

Boothwyn Apothecary
2341 Chichester Ave
Boothwyn, PA 19061
610-485-1130

Boothwyn Pharmacy
221 Gale Lane
Kennett Square, PA 19348
1-800-476-7496

Related link: https://www.bpimedicalsupply.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Insurance

EPIC Continues Expansion of Employee Benefits Practice with a new Pharmacy Practice Leader

NEW YORK, N.Y. -- EPIC Insurance Brokers and Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today they are continuing to expand their employee benefits resources with the addition of a new Pharmacy Practice Leader, Bob Eisendrath. We are also pleased to announce that we have promoted Craig Hasday to President, National Employee Benefits Practice leader and Cindy Santangelo to National Voluntary Benefits Practice Leader.

Bob Eisendrath brings a strong background in pharmacy benefit management. He brings experience both in sales and national account management, with CVS Caremark for 20 years where he was most recently Area Vice President for Coalition Business. "The addition of Bob will further strengthen our Pharmacy consulting practice as he leads the team through the rapidly changing legislative and therapeutic landscape as our clients grapple with increasing pharmacy prices, one of the most problematic components of escalating cost," said Craig Hasday, National Employee Benefits Practice Leader.

Craig Hasday has been promoted to President, National Employee Benefits Leader. Said Steve Denton, President, EPIC Holdings, "For the past eighteen months, Craig has led EPIC's National Employee Benefits Operations Board. In that role, Craig has worked closely with the geographic employee benefits leaders and has done an incredible job bringing our national teams together."

During this time, EPIC has seen increased communication and enhancements across the board in service offerings for our clients. Further, EPIC has seen great improvement in revenue growth, profitability, and integration of its vast employee benefits platform. Employee Benefits revenue of over $170 million which represents over 20% of EPIC's retail revenue.

Promoting Cindy Santangelo to the new national role as lead of EPIC's Voluntary Benefits practice highlights EPIC's growing focus on the changing workplace dynamic of offering personalized benefits. Santangelo has been with EPIC for 12 years and spent the past 5 years building and growing the Voluntary Benefits practice within EPIC's national Employee Benefit platform. She brings a wealth of knowledge to her role in employee paid worksite benefits consulting as she fully understands how to create a customized program to meet individualized needs.

"We are fortunate to have someone with her expertise on our team to support our clients and other EPIC consultants," said John Gaffney, VP. National Employee Benefits Operations.

About EPIC Insurance Brokers & Consultants

EPIC is a unique and innovative retail property and casualty and employee benefits insurance brokerage and consulting firm. EPIC has created a values-based, client-focused culture that attracts and retains top talent, fosters employee satisfaction and loyalty and sustains a high level of customer service excellence.

EPIC team members have consistently recognized their company as a "Best Place to Work" in multiple regions and as a "Best Place to Work in the Insurance Industry" nationally.

EPIC now has more than 2,600 team members operating from more than 70 offices across the U.S., providing Property and Casualty, Employee Benefits, Specialty Programs and Private Client solutions to EPIC clients.

With run rate revenues greater than $730 million, EPIC ranks among the top 15 retail insurance brokers in the U.S. Backed and sponsored by Oak Hill Capital Partners, the company continues to expand organically and through strategic acquisitions across the country. For additional information, please visit https://www.epicbrokers.com/.

Related link: https://www.epicbrokers.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Drugs and Pharmaceuticals, Free News Articles

iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y. -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

ASH abstracts are now available at https://www.hematology.org/.

Oral Presentation:

Title: First-in-Human Trial of BCMA-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction
Session: 721. Abstract Number: 38
Saturday, December 7, 2019: 7:45 a.m.
Valencia BC (W415BC), Level 4 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162353

Poster Presentation:

Title: First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma
Session: 626. Abstract Number: 2881
Sunday, December 8, 2019, 6 p.m. to 8 p.m.
Hall B, Level 2 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162340

About BCMA-CD19 cCAR therapy

BCMA-CD19 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressing on a T-cell, directed against the surface proteins BCMA and CD19. The diseases treated by BCMA-CD19 cCAR could include autoimmune disorders, and organ rejection. BCMA is expressed in plasma cells, while CD19 is related to B-cells. BCMA-CD19 cCAR is designed to completely remove antibody-producing "roots", plasma cells and B cells, and then re-set the immune system for treating antibody-mediated autoimmune disorders or organ rejections.

BCMA-CD19 cCAR is also aimed to treat multiple myeloma, a challenging disease due to the heterogeneity of myeloma cells, which renders single-antigen targeting CAR T-cell therapy ineffective. BCMA-CD19 cCAR is proposed to target both bulky myeloma cells expressing BCMA, and myeloma stem cells expressing CD19 to effectively eradicate the disease.

About CD4-specific CAR (CD4 CAR) therapy

CD4-specific CAR with a safety switch is designed to treat peripheral T cell lymphoma as CD4 is uniformly expressed on most mature T cell lymphoma, and transient depletion of CD4 is expected. The diseases treated by CD4 CAR could include peripheral T-cell lymphoma (NOS), Sezary syndrome/cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T cell lymphoma, T-cell prolymphocytic leukemia, T-cell acute lymphoblastic leukemia/lymphoma and T-cell large granular lymphocytic leukemia. Most of these diseases are difficult to treat, with dismal prognoses. An IND has been approved for iCell Gene Therapeutics to initiate a multi-site clinical trial at Stony Brook University Hospital and University of Louisville.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Clinical studies on our CARvac, T-cell targeted CARs, Compound CARs, Non-gene edited universal CARs and C-TPS1 (depletion of TREG, blockage of PD-L1 pathways and stimulation of tumor infiltrating lymphocytes) for solid tumors are ongoing in the US and in China.

For more information, please visit http://icellgene.com/

Contact:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

American Medical Marijuana Physicians Association’s 2019 Annual Meeting Hosted Over 300 Attendees and Physicians

ORLANDO, Fla. -- The American Medical Marijuana Physicians Association (AMMPA) held their 3rd Annual Conference on October 4-6 at the Hilton Orlando Lake Buena Vista. More than 300 medical marijuana practitioners and physicians from across the nation and other countries around the world attended the 3-day conference.

The meeting provided educational presentations, networking and panel discussions with thought-leaders dedicated to the research and utilization of medical cannabis to improve the health of their patients. AMMPA is the largest medical cannabis association in the world, boasting the highest membership base for an organization of its kind. The AMMPA Annual Conferences are dedicated to medical research and education, presenting on the health benefits of medical cannabis.

This year, the AMMPA Annual Conference featured Keynote Speaker Nikki Fried, the 12th Florida Commissioner of Agriculture and Consumer Services. Commissioner Fried is a strong advocate for medical marijuana and created a Medical Marijuana Advisory Committee this past Summer.

A number of recognized medical marijuana physician leaders attended and over 20 nationally recognized speakers participated in lectures and panel discussions. In addition to Commissioner Fried, our second Keynote Speaker was Professor Hinanit Koltai, PhD, a Senior Research Scientist from the Volcani Center in Israel. Our panel also featured Jade Green, CEO of Jade Green Consulting, an all-female canna-business consultancy, based out of Los Angeles.

The faculty engaged the audience in a series of lectures and panel discussions on the recent literature relevant to the benefits of cannabis in addressing medical conditions such as Cancer, Seizure Disorders, Anxiety, HIV, Chronic Pain, Migraines, and Autism. The Annual Conference was supported by a host of medical cannabis industry leaders including our Premier Emerald Sponsor, Leafly.

About the American Medical Marijuana Physicians Association (AMMPA):
The American Medical Marijuana Physicians Association is a membership driven association, focusing on providing physicians with the resources they need to safely and effectively utilize medical marijuana recommendations as an alternative treatment modality for their patients. AMMPA serves as a physician advocate helping to outline practice risks and benefits, educational requirements, compliance issues, and aggregates its members to allow for a unified voice representing all physicians currently interested in cannabinoid medicine. Our members are leaders in the nation that provide expertise to the public regarding research, education, speaking engagements, seminars, and industry recommendations.

American Medical Marijuana Physicians Association, 1215 E. Robinson Street, Orlando, FL 32801.

Website: https://ammpa.net/

MEDIA ONLY CONTACT:
Savara Hastings
321-917-3212
info@ammpa.net

*PHOTO: https://www.Send2Press.com/300dpi/19-1108s2p-ammpa-event-300dpi.jpg
*Photo Caption - Pictured (L-R): Jade Green, CEO Jade Green Consulting; Savara Hastings, AMMPA Executive Director; Dr. Jaime Snarski, AMMPA Board Member; Megan Zalonka, AMMPA Communications Director.

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Hospitals and Nursing, NonProfit and Charities

C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO

ST. LOUIS, Mo. -- C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel, 1973 Craigshire Road, St. Louis, MO 63146; Telephone: +1 (314) 434-0100.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit: https://cdifffoundation.org/2019-guest-speakers/

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by an independent patient advocacy Grant from Merck & Co., Inc., and the members of the C Diff Foundation are truly grateful.

Attendee Paul Feuerstadt MD, FACG, AGAF stated, "The annual C Diff Foundation conference and health expo is an essential conference for me to attend, given the comprehensive presentations about epidemiology, disease state, patient experience, infection control and innovations with treatment of C. difficile. The level of detail and data presented has a wonderful balance that is understandable for someone casually interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. EST (www.cdiffradio.com) sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-cdiff-nov-expo-300dpi.jpg

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.